Antibe Therapeutics Advances Development of ATB-352 in Wake of Growing Global Opioid Epidemic

TORONTO, CANADA — (April 26, 2017) – Antibe Therapeutics Inc. (“Antibe” or the “Company”) (TSXV: ATE, OTCQX: ATBPF) is pleased to announce that is has formally commenced Investigational New Drug (“IND”) enabling pre-clinical studies for its second pipeline drug, ATB-352, a non-addictive, potent analgesic for the treatment of severe pain.

Dan Legault, Antibe’s CEO, commented, “There has never been a greater need for a potent, non-addictive pain-killer as the opioid crisis continues to escalate and claim lives across the globe. The unfortunate truth is that physicians lack access to viable, non-addictive treatment options for cases of severe pain, and the pharmaceutical industry has struggled to innovate breakthrough therapies in this area. Antibe believes ATB-352 has great potential to fill this void, and the latest data continue to support this claim. With the recent announcements of our progress with our lead drug, ATB-346, we feel we are now in a position to rapidly move forward with ATB-352 in parallel.”

ATB-352 is a hydrogen sulfide-releasing derivative of ketoprofen, one of the most potent nonsteroidal anti-inflammatory drugs (“NSAIDs”) commonly prescribed for acute pain; however, it is also one of the most damaging NSAIDs to the GI system. In contrast, ATB-352 has been shown to be GI-safe and was confirmed last October to be non-addictive, rendering it a potentially important solution for the growing global opioid epidemic.

As part of its latest pre-clinical studies, Antibe examined the pharmacokinetics (“PK”) of ATB-352 and completed a maximum tolerated dose (“MTD”) study this month. These early data suggest that ATB-352, like ATB-346, can be administered once daily, a favourable characteristic for commercial purposes due to its convenience and positive impact on patient compliance.

About Antibe Therapeutics Inc.
Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug ATB-346 targets the global need for a safer drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a safer, non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. www.antibethera.com

Antibe's subsidiary, Citagenix Inc. ("Citagenix"), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become an important source of knowledge and experience for bone regeneration in the Canadian medical device industry. Citagenix is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Information
This news release includes certain forward-looking statements, which may include, but are not limited to, the growth of product sales, engaging new distributors and independent representatives, the completion of financing transactions and the licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", "propose" and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s ability to secure additional financing, its ability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.

Contact Information
Antibe Therapeutics Inc.
Dan Legault
Chief Executive Officer
Tel: +1 416-473-4095
dan.legault@antibethera.com

Please sign up to our mailing list to receive regular news updates via e-mail.